Kynexis extends Series A to €97m to advance cognitive disorder drug
Kynexis has closed a €40 million Series A extension bringing the company’s total Series A financing to €97 million ($110 million). The financing was led by new investor Novartis Venture Fund, with participation from existing investors Forbion, Ysios Capital, and Sunstone Life Science Ventures. In… Read More